嵌合型抗原受体T细胞在恶性黑色素瘤中应用进展  

Update of chimeric antigen receptor T cell in malignant melanoma

作　　者：张立坤 岳武恒 邹征云[3] ZHANG Likun;YUE Wuheng;ZOU Zhengyun(Department of Dermatology,Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Taicang 215400,China;Department of Oncology,Taicang TCM Hospital Affiliated to Nanjing University of Chinese Medicine,Taicang 215400,China;The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China)

机构地区：[1]南京中医药大学太仓附属医院皮肤科,江苏太仓215400 [2]南京中医药大学太仓附属医院肿瘤科,江苏太仓215400 [3]南京大学医学院附属鼓楼医院肿瘤中心,江苏南京210008

出　　处：《中国麻风皮肤病杂志》2024年第1期59-65,共7页China Journal of Leprosy and Skin Diseases

基　　金：国家自然科学基金项目(编号:82073365);太仓市科技计划项目(编号:TC2020JCYL02)。

摘　　要：恶性黑素瘤细胞膜表达有多种生物标志物,可作为治疗靶点开发针对性的嵌合型抗原受体T细胞(CAR-T),CAR-T目前对恶性黑素瘤中GD2、HER2、CD70、Gp100、NYESO-1等靶点已表现出良好的疗效。本文旨在梳理恶性黑素瘤CAR-T靶点及临床进展,分析工程化T细胞的挑战与应对之策,以期CAR-T应用于恶性黑素瘤临床实践。There are a variety of biomarkers expressed on the membrane of malignant melanoma cells,which can be used as therapeutic targets to develop targeted chimeric antigen receptor T cells(CAR-T).CAR-T has shown good effects on GD2,HER2,CD70,Gp100,NYESO-1 and other targets in malignant melanoma.This paper aims to review the targets and clinical progress of CAR-T cells for malignant melanoma,and analyze the challenges and countermeasures of engineered T cells,in order to apply CAR-T cells to the clinical practice of malignant melanoma.

关 键 词：恶性黑素瘤 嵌合型抗原受体T细胞 肿瘤免疫微环境 

分 类 号：R739.5[医药卫生—肿瘤]